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Parenteral iron nephrotoxicity: Potential mechanisms and con-
sequences.
Background. Parenteral iron administration is a mainstay of
anemia management in renal disease patients. However, con-
cerns of potential iron toxicity persist. Thus, this study was
conducted to more fully gauge iron toxicologic profiles and po-
tential determinants thereof.
Methods. Isolated mouse proximal tubule segments (PTS)
or cultured proximal tubular [human kidney (HK-2)] cells
were exposed to four representative iron preparations [iron
sucrose (FeS), iron dextran (FeD), iron gluconate (FeG), or
iron oligosaccharide (FeOS)] over a broad dosage range (0, 30
to 1000 lg iron/mL). Cell injury was assessed by lactate dey-
hdrogenase (LDH) release, adenosine triphosphate (ATP) re-
ductions, cell cytochrome c efflux, and/or electron microscopy.
In vivo toxicity (after 2 mg intravenous iron injections) was
assessed by plasma/renal/cardiac lipid peroxidation [malondi-
aldehyde (MDA)], renal ferritin (protein)/heme oxygenase-1
(HO-1) (mRNA) expression, electron microscopy, or postiron
injection PTS susceptibility to attack.
Results. In each test, iron evoked in vitro toxicity, but up to
30× differences in severity (e.g., ATP declines) were observed
(FeS > FeG > FeD = FeOS). The in vitro differences paral-
leled degrees of cell (HK-2) iron uptake. In vivo correlates of
iron toxicity included variable increases in renal MDA, ferritin,
and HO-1 mRNA levels. Again, these changes appeared to par-
allel in vivo (glomerular) iron uptake (seen with FeS and FeG,
but not with FeD or FeOS). Iron also effected in vivo alter-
ations in proximal tubule cell homeostasis, as reflected by the
“downstream” emergence of tubule resistance to in vitro oxi-
dant attack.
Conclusion. Parenteral iron formulations have potent, but
highly variable, cytotoxic potentials which appear to parallel
degrees of cell iron uptake (FeS > FeG  FeD or FeOS). That
in vitro injury can be expressed at clinically relevant iron con-
centrations, and that in vivo glomerular iron deposition/injury
may result, suggest caution is warranted if these agents are to
be administered to patients with active renal disease.
1See Editorial by Alam et al, p. 457.
Key words: iron dextran, iron sucrose, iron gluconate, oxidant stress,
heme oxygenase 1.
Received for publication December 23, 2003
and in revised form January 29, 2004
Accepted for publication February 11, 2004
C© 2004 by the International Society of Nephrology
Administration of parenteral iron has become a main-
stay for treating anemia in patients with end-stage
renal disease (ESRD). This practice is required in
order to offset dialysis-related blood (iron) loss, and the
need to optimize hematopoietic responsiveness to exoge-
nous erythropoeitin (Epo) therapy [1–3]. While generally
regarded as safe, anaphylactic/oid reactions have been
noted following intravenous iron injection, most com-
monly but not exclusively, with dextran preparations [4].
In addition to allergic reactions, each currently employed
parenteral iron formulation [e.g., iron dextran (FeD), iron
sucrose (FeS), and iron gluconate (FeG)] has the poten-
tial to induce oxidative stress [5–9]. For example, when
administered intravenously, these agents may induce
free radical generation [10] and lipid peroxidation [5],
processes which can induce acute endothelial dysfunc-
tion (e.g., as denoted by perturbed forearm endothelial-
dependent vasodilation) [10]. Additional support for the
concept of iron-induced toxicity comes from a recent re-
port [11] which indicates that clinically achievable con-
centrations of FeG or FeS can impair polymorphonuclear
cell (PMN)/transendothelial migration. This could con-
tribute to infectious complications in dialysis patients.
While the above evidence suggests potential acute tox-
icities, the long-term consequences of parenteral iron
administration remain largely unknown. In this regard,
it is noteworthy that iron-mediated oxidative stress can
contribute to both atherogenesis [12–17] and chronic in-
flammation [18–22], each of which are leading causes of
morbidity and mortality in ESRD patients [23–25]. Fur-
thermore, because parenterally administered iron has
direct glomerular, and as well as tubular access (via per-
itubular capillaries), it is conceivable that it might con-
tribute to glomerular and/or tubulointerstitial disease
progression [26–29]. That intravenous iron + Epo ther-
apy is currently being administered to pre-ESRD patients
underscores these concerns.
Given that parenteral iron therapy is likely to remain
an integral component of renal disease patient man-
agement, it is imperative to better define its potential
cytotoxic effects, and to ascertain whether different toxi-
city profiles exist amongst currently employed parenteral
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iron formulations. Indeed, in a recent study performed in
this laboratory using suprapharmacologic iron doses [5], a
clear gradation of toxicity was apparent amongst four test
agents [from most to least severe: FeS  FeG  FeD = Fe
oligosaccharide (FeOS)]. However, the reason(s) for this
differential in vitro toxicity, if it might be observed with
more clinically relevant iron concentrations, whether in
vivo toxicologic correlates exist, and the nature of un-
derlying pathogenic mechanisms were not well defined.
Hence, the present study was undertaken utilizing a num-
ber of experimental models (freshly isolated mouse prox-
imal tubules, cultured human proximal tubular cells, and
in vivo mouse experiments) to gain additional insights.
METHODS
Proximal tubule segment (PTS) experiments
Preparation of isolated mouse proximal tubules. Prox-
imal tubules were isolated from normal CD-1 male mice
(25 to 35 g) (Charles River, Wilmington, MA, USA), as
previously described [30]. In brief, the mice were deeply
anesthetized with pentobarbital (4 to 5 mg intraperi-
toneally), and the kidneys were resected through a mid-
line abdominal incision. They were iced, the cortices were
dissected, and the tissues were subjected to collagenase
digestion. The tissues were passed through a stainless
steel mesh, and then viable PTS were collected after
pelleting through 32% Percoll [30, 31]. The recovered
tubules were suspended in an experimentation buffer
consisting of (in mmol/L): NaCl, 100; KCl, 2.1; NaHCO3,
25; KH2PO4, 2.4; MgSO4 1.2; MgCl2, 1.2; CaCl2, 1.2;
glucose, 5; alanine, 1; Na lactate, 4; Na butyrate, 10;
36 kD dextran, 0.6%; and gassed with 95% O2/5% CO2,
pH 7.44). The final tubule protein concentration was ∼2
to 4 mg/mL. Each PTS preparation was rewarmed to 37◦C
in a heated shaking water bath and divided into four to
six equal aliquots (1.25 mL) in 10 mL Erlenmyer flasks,
depending on the needs of individual experiments (see
below).
Comparative effects of iron preparations on proxi-
mal tubule adenosine triphosphate dehydrogenase (ATP)
content.
Dose response experiments. The purpose of this
study was to compare dose-response toxicity effects
of four test iron preparations. Given that previous
studies demonstrated that mitochondrial dysfunction,
as assessed by reductions in tubule ATP production,
is a sensitive marker of iron toxicity [5, 31], tubule
ATP concentrations, as well as lethal cell injury [% lac-
tate dehydrogenase (LDH) release], were chosen as test
biologic end points. Twelve individual sets of PTS were
prepared, each was divided into five equal aliquots,
and these were incubated ×30 minutes in a 37◦C shak-
ing water bath in the presence of 95% O2/5% CO2,
under the following conditions: (1) control incubation;
(2) 1000 lg/mL iron addition; (3) 500 lg/mL iron addi-
tion; (4) 250 lg/mL iron addition; and (5) 125 lg/mL iron
addition. Each individual tubule preparation was used to
test one of the four iron preparations: (1) FeS (Venofer)
(American Regent, Shirley, NY, USA); (2) FeD
(INFeD) (Watson Pharmaceuticals, Morristown, NJ,
USA); (3) FeG (Ferrlecit) (Watson Pharmaceuticals);
and (4) FeOS, an iron preparation currently in clinical
trials (Pharmacosmos, Copenhagen, DK). In all, each of
these preparations were tested in three separate dose-
response experiments. After completing the 30-minute
incubations, a sample of each aliquot was removed, ade-
nine nucleotides were extracted in trichloroacetic acid,
and then the samples were analyzed for ATP by high-
performance liquid chromatography (HPLC) (nmol/mg
tubule protein) [32]. An aliquot of each tubule suspension
was also used to determine % LDH release.
pH control experiment. Because FeS stock solution
has a pH of approximately 10.5, and because a high pH
can induce cytotoxicity [33], a control for the above FeS
additions was conducted with an equivalent amount of
sucrose (300 mg/mL) with its pH adjusted to 10.5 by
1 N NaOH addition. Aliquots from four sets of tubules
were incubated either under control conditions or with
62.5 lL of the alkaline sucrose solution (equivalent
to the volume of the 1000 lg/mL FeS dosage). After
30-minute incubations, ATP concentrations and % LDH
release were assessed.
Effects of low dose FeS and FeG on tubule ATP
concentrations. The above dose-titration experiments
indicated that FeS and FeG had the greatest suppres-
sive effects on tubule ATP concentrations, with reduc-
tions being apparent at the lowest test concentration
(125 lg iron/mL) (see Results section). The following ex-
periment ascertained whether ATP reductions could be
induced by even lower iron concentrations (i.e., within
clinically achievable plasma iron concentrations). Four
sets of tubules were prepared, each was divided into
five equal aliquots, and incubated ×30 minutes as fol-
lows: group 1, control conditions; groups 2 and 3, with
30 or 60 lg/mL FeS iron; and groups 4 and 5, with 30 or
60 lg/mL FeG iron. ATP levels and LDH release were
then assessed.
In vivo mouse experiments
Assessment of lipid peroxidation following intravenous
iron treatment. The following experiments were under-
taken to ascertain the relative degrees of lipid peroxida-
tion induced by three representative test iron compounds:
FeD, FeS, and FeG. These three compounds were selected
because they manifested the greatest differential toxic-
ity in the above described proximal tubule experiments
(see Results section). Mice (N = 18) were placed in non-
traumatic restraining cages, and they were injected via
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Table 1. Mouse primers for quantitating heme oxygenase 1 (HO-1) mRNA in renal cortex
Genes Primer sequences Polymerase chain reaction conditions Product size
Mouse 5′-CTG CCA TTT GCA GTG GCA AAG TGG-3′ 94◦C – 45 sec; 57◦C – 45 sec; 437 bp
GAPDH 5′-TTG TCA TGG ATG ACC TTG GCC AGG-3′ 72◦C – 45 sec; 28 cycles
Mouse 5′-AAC ACA AAG ACC AGA GTC CCT CAC-3′ 94◦C – 45 sec; 57◦C – 45 sec; 288 bp
HO-1 5′-CAA GAG AAG AGA GCC AGG CAA GAT-3′ 72◦C – 45 sec; 28 cycles
Primer sequences used for quantitating HO-1 mRNA in mouse renal cortex 4 hours following intravenous iron treatment (see text). Glyeraldehyde-3-phosphate
dehydrogenase (GAPDH) was quantified as a “housekeeping gene.”
the tail vein with either 2 mg of iron (N = 4 of each of the
above iron preparations), or with a sham tail vein saline
injection (N = 6). The mice were then released from
the restrainers and, 90 minutes later, they were deeply
anesthetized with pentobarbital, as above. The abdomi-
nal cavities were opened, a plasma sample was obtained
from the inferior vena cava, and then one kidney per
animal was resected. The thorax was opened and the
heart was removed. The tissues were placed on an iced
plate. A piece of renal cortex and of cardiac apex were
resected, the tissues rinsed in iced saline to remove con-
taminating blood, and then ∼75 mg of renal cortex or
heart tissue were homogenized in 1 mL of iced phosphate-
buffered saline (PBS) containing 25 mmol/L desferriox-
amine (DFO) to chelate any free iron which may have
been generated during this process. Samples of tissue ho-
mogenates (200 lL) were then assayed for malondialde-
hyde (MDA) concentrations by the thiobarbituric acid
method [34]. Tissue MDA concentrations were expressed
as nmol/mg tissue protein. Plasma samples (200 lL), to
which 25 mmol/L DFO was added, were also assayed for
MDA with values being expressed as nmol/mL.
Parenteral iron effects on renal ferritin and heme
oxygenase-1 (HO-1) expression. The following experi-
ments were conducted to ascertain whether, and to what
degree, the four test iron preparations impact renal corti-
cal homeostasis, as assessed by the potential induction of
ferritin and HO-1 proteins (redox-sensitive indicators).
To this end, mice received every other day tail vein in-
jections of 2 mg iron, administered as either FeS (N =
5), FeG (N = 5), INFeD (N = 5), or FeOS (N = 4).
Each group of mice had their own simultaneous control
groups which received equal volume tail vein saline in-
jections. Approximately 24 hours following the last of the
three injections, the mice were anesthetized with pento-
barbital, the kidneys were removed, and the cortices were
dissected on an iced plate.
Western blotting. The above noted renal cortical tis-
sue samples were extracted for protein and probed by
Western blot for ferritin and HO-1, using previously de-
scribed general methodologies [35]. In the case of ferritin,
25 lg of protein extract were electrophoresed through
a 12% Bis-Tris acrylamide Nupage gel (Invitrogen Life
Technologies, Carlsbad, CA, USA) and probed with goat
antiferritin antibody (catalog number SC-14416) (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), according
to manufacturer’s instructions. For HO-1 detection,
50 lg of protein extract was electrophoresed as described
above, and probed with rabbit anti-HO-1 antibody (cat-
alog number SC-10789) (Santa Cruz Biotechnology) as
the primary antibody as per manufacturer’s instructions.
Secondary detection of the anti-ferritin and anti-HO-1
antibodies was performed with either horseradish per-
oxidase (HRP)-labeled donkey antigoat IgG (catalog
number SC-2020) (Santa Cruz Biotechnology) for fer-
ritin or with HRP-labeled donkey antirabbit IgG (cata-
log number NA 934) (Amersham-Pharmacia, Piscataway,
NJ, USA) for HO-1. Detection was by enhanced chemi-
luminescence (ECL Kit) (Amersham-Pharmacia). West-
ern blot semiquantitative analysis was performed by band
optical density scanning. Nonspecific secondary antibody
staining was ruled out by the fact that the secondary anti-
body, in the absence of the primary antibody, did not iden-
tify the relevant protein bands (ferritin, ∼25 kD; HO-1,
∼32 kD). Equal protein loading/transfer was verified by
India ink staining. A positive control consisted of renal
cortical protein samples from mice 18 hours postinduc-
tion of glycerol induced-acute renal failure (which up-
regulates both HO-1 and ferritin) [36].
HO-1 mRNA expression following iron treatment.
Stress induced changes in tissue ferritin concentra-
tions are largely determined by posttranslational events,
whereas HO-1 expression is regulated via oxidant stress-
induced HO-1 gene transcription [37]. Therefore, to gain
further insights into relative degrees of iron-induced oxi-
dant stress, mice were injected with either FeD, FeG, FeS,
or FeOS, as noted above (N = 4 to 6 per group). Controls
consisted of ten mice subjected to tail vein saline injec-
tions. Four hours later, the mice were anesthetized with
pentobarbital, and the kidneys resected. The renal corti-
cal tissues were immediately placed into TRIzol reagent
(Invitrogen Life Technologies) and total RNA was ex-
tracted according to the manufacturer’s instructions. The
final RNA pellet was brought up in RNase-free water to
an approximate concentration of 3 mg/mL.
Reverse transcription (RT) and polymerase chain re-
action (PCR) were performed using the 1st-Strand Syn-
thesis Kit for RT-PCR (Ambion Inc., Austin, TX, USA),
as previously described in detail [38]. The specific primers
for HO-1 and glyceraldehyde-3-3-phosphate dehydroge-
nase (GAPDH) were designed with 50% to 60% GC
composition (see Table 1). The similarity in annealing
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temperature, but dissimilarity in PCR products, enabled
a multiplexed reaction whose products were analyzed
by agarose gel electrophoresis and ethidium bromide
staining. cDNA bands were visualized and quantified by
densitometry with a Typhoon 8600 scanner (Amersham
Pharmacia Biotech). HO-1 cDNA bands were expressed
as ratios to the simultaneously obtained GAPDH cDNA
bands, the latter used as a housekeeping gene.
Renal histology. To assess whether parenteral iron
treatment might induce structural renal alterations, mice
which were subjected to the above intravenous iron treat-
ment protocols (2 mg iron every other day × 1 week;
N = 2 for each test agent) or to sham saline injections
(N = 3). One day following the last injection, the kid-
neys were harvested, and prepared for either light or
electron microscopy. For light microscopy, a midline slice
of kidney (cortex to papilla) was fixed in 10% formalin
and 4 l paraffin-embedded sections prepared and stained
with hematoxylin and eosin. For electron microscopy,
1 mm cubes of renal cortex were fixed by immersion in
1/2 strength Karnovsky’s fixative. Tissue sections were cut
and evaluated by transmission electron microscopic anal-
ysis, as previously described [39]. At least four glomeruli
from two different kidneys were extensively examined by
electron microscopy.
Cultured proximal tubular [human kidney (HK-2)]
cell experiments
Cytotoxicity and cellular loss of cytochrome c. The fol-
lowing experiment was undertaken to further ascertain
relative degrees of iron-mediated cytotoxicity, as assessed
by % LDH release and extracellular cytochrome c re-
lease (a marker of mitochondrial damage) [31]. To these
ends, immortalized human proximal tubular (HK-2) cells
were cultured in T-75 flasks with keratinocyte serum-free
medium (K-SFM) and passaged by trypsinization every
5 to 6 days, as previously described [40]. For experimen-
tation, the cells were seeded into 18 T-25 flasks. After
an overnight postseeding recovery period, the cells were
divided into six groups of three flasks each: (1) control
cells (N = 3); (2) incubation with 100 lg/mL FeS iron;
(3) incubation with 100 lg/mL FeG iron; (4) incubation
with 100 lg/mL FeD iron; (5) incubation with 100 lg/mL
FeOS iron; and (6) a second group of control incubated
cells. The cells were maintained under routine culture
conditions for 3 days. At the completion of the incuba-
tions, % LDH release was determined. Then, the cells
which remained attached to the flasks were recovered
by scraping with a cell scraper, and washed with Hanks’
balanced salt solution (HBSS), and pelleted. The pellets
were photographed with a digital camera. Then, cell pro-
tein extracts were prepared and probed for cytochrome
c by Western blotting [31]. An equal amount of protein
(8 lg) from each cell sample was applied.
Electron microscopic analysis of iron effects on HK-2
cell morphology. The following experiment was under-
taken to ascertain the effect of the four test iron prepa-
rations on HK-2 cell morphology. To this end, a 6-well
Costar plate was seeded with HK-2 cells and allowed to
grow to near confluence. One well each was subjected to
the following conditions: (1) control incubation; (2) incu-
bation with 100 lg FeS iron; (3) incubation with 100 lg
FeG iron; (4) 100 lg FeD iron; (5) 100 lg of FeOS iron;
and (6) additional control culture. After an 18-hour incu-
bation, the cell culture medium in each well was removed,
and then a mixture of 1 part of 1/2 strength Karnovsky’s
fixative/1 part fresh culture medium was added to the
adherent cells. The cells were allowed to fix overnight.
After dehydration and alcohol fixation, groups of cells
were randomly lifted off the plates by applying small resin
blocks to the monolayers. These blocks were then cut
and processed for transmission electron microscopy, as
previously described [41].
Combination in vivo/in vitro experiments
Intravenous iron injection with subsequent in vitro anal-
ysis of cytoresistance. A feature of acute sublethal renal
tubular injury is the subsequent emergence of partial cell
resistance to further attack [42–45]. In particular, iron-
mediated injury induces resistance to further oxidative
damage [36, 42]. Hence, the goal of this experiment was
to ascertain whether parenteral iron administration can
induce sublethal proximal tubular injury, and that this
prior injury is denoted by the emergence of cytoresis-
tance to subsequent iron-mediated tubular attack. To this
end, four mice were injected with 2 mg of FeS via the tail
vein (0.1 mL). Four mice subjected to equal saline tail
vein injections served as controls. The mice were then
provided with free food and water access (preliminary
data indicated that no difference in food intake/body
weight resulted from the iron injection). Eighteen hours
postinjections, they were anesthetized with pentobarbi-
tal, the kidneys resected, and cortical proximal tubules
were isolated, as above. The eight preparations (four
postiron injection; four postsaline injection) were each
divided into five equal tubule aliquots as follows: (1) con-
trol incubation (95% O2/5% CO2); (2) hypoxic incuba-
tion (95% N2/5% CO2); (3) exposure to 100 lmol/L an-
timycin A (a mitochondrial inhibitor); or (4) addition of
25 lmol/L ferrous ammonium sulfate (iron), complexed
to the siderophore hydroxyquinoline (FeHQ), permitting
iron to gain intracellular access [42]. After completing
15-minute incubations under each of these conditions,
the extent of lethal cell injury was gauged by % LDH
release. The results for the control and Venofer pretreat-
ment groups were compared.
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Fig. 1. Proximal tubular segment adenosine triphosphate (ATP) con-
centrations following 30-minute incubations with four test iron prepara-
tions: iron dextran (FeD), iron oligosaccharide (FeOS), iron gluconate
(FeG), and iron sucrose (FeS). ATP concentrations are presented as
nmol/mg tubule protein. FeD and FeOS caused only minimal ATP de-
clines, and these were apparent at only the 1000 lg/mL iron concentra-
tion. In contrast, steep ATP declines were observed with both FeS and
FeG, with the degree of ATP reductions being statistically greater with
FeS vs. FeG (P < 0.0001; all dose-paired comparison). Standard error
bars are not shown for clarity sake, but were all <0.4 nmol/mg protein.
Calculations and statistics
All values are presented as means ± 1 SEM. Statistical
comparisons were made by paired or unpaired Student
t testing, as per the nature of the experiment. If multiple
comparisons were made, the Bonferroni correction was
applied.
RESULTS
Isolated tubule experiments
Proximal tubule ATP concentrations in response to 125
to 1000 lg/mL iron exposures. As shown in Figure 1,
each of the test iron preparations caused dose depen-
dent reductions in tubule ATP concentrations. The FeOS
and FeD curves did not significantly differ, and statisti-
cally significant ATP reductions were observed at only
the highest tested concentration (1000 lg/mL of iron;
P < 0.04 vs. their respective controls). In contrast, FeS
and FeG each induced steep dose-response curves, clearly
much more severe than those observed with either FeOS
or FeD. FeS caused the most severe ATP depressions,
with ∼50% greater ATP losses being observed vs. their
corresponding FeG results (P < 0.0001 in an overall com-
parison between paired concentrations).
% LDH release with the 125 to 1000 lg/mL iron dosage
range. The 95% confidence band for % LDH release for
control tubules was 8% to 13%. In the above-described
30-minute titration experiments, only FeS raised % LDH
release above this normal range, but this was observed
only at the two highest test concentrations (41 ± 3%,
14 ± 1%, and 13 ± 1% with 1000 lg/mL, 500 lg/mL, and
250 lg/mL iron doses, respectively) (data not shown).
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Fig. 2. Proximal tubular segment adenosine triphosphate (ATP) con-
centrations with low dose (30 and 60 lg/mL) iron sucrose (FeS) and iron
gluconate (FeG) exposures. Both drugs caused significant ATP depres-
sions at the 60 lg/mL concentration. Each drug also tended to depress
ATP concentrations even at the 30 lg/mL dosage, but only the FeS
result achieved statistical significance (P < 0.02 vs. controls).
Each of the other test compounds (FeD, FeG, and
FeOS) failed to raise % LDH release above control val-
ues (≤13%) even with application of 1000 lg/mL iron
concentrations.
pH controls for high dose Venofer additions. Addition
of alkaline sucrose solution (pH 10.5), did not reproduce
FeS cytotoxic effects. First, it tended to raise, rather than
lower, tubule ATP concentrations (pH 10.5, 8.4 ± 0.6;
controls, 8.0 ± 0.5 nmol/mg protein). Second, % LDH
release was 14 ± 1% with alkaline sucrose incubation,
compared to 41 ± 3% with the 1000 lg/mL FeS addition.
Third, even the highest test dose of FeS (1000 lg/mL)
had only a small effect on tubule suspension pH, raising
it from 7.44 to 7.8. Lesser amounts of FeS addition had
no discernible pH effect.
ATP concentrations and LDH release with “low dose”
(30 and 60 lg/mL) iron concentrations. As shown in
Figure 2, even when added in a 30 or 60 lg iron/mL
dose, FeS still caused statistically significant reductions
in tubule ATP concentrations, compared to co-incubated
control tubules. FeG also lowered ATP at these two iron
concentrations, but the result was statistically significant
only at the 60 lg/mL concentration (Fig. 2). None of these
incubations caused a significant increase in LDH release
(range for controls and iron compounds, 9% to 11%).
In vivo experiments
MDA levels following parenteral iron treatment. As
shown in Figure 3A, each of the iron compounds induced
statistically significant plasma MDA increments, rising
well above the upper 95% confidence limit (shown by hor-
izontal line) for normal plasma MDA values. The plasma
MDA increase was ∼2× as great with FeD, compared
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Fig. 3. Malondialdehyde (MDA) concentrations in plasma (A), renal cortex (B), and apical myocardium (C) following intravenous iron dextran
(FeD), iron gluconate (FeG), or iron sucrose (FeS) injection. Whereas FeD caused the greatest plasma MDA increase, it failed to induce renal
cortical lipid peroxidation (horizontal lines are the upper limit of the 95% confidence interval for normal plasma or tissue MDA levels). Minimal
cardiac lipid peroxidation resulted, and it was significant only with FeS treatment. Thus, these results indicate that while intravenous irons can cause
in vivo lipid peroxidation, the degrees to which they do so are both compound, and target tissue, dependent.
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Fig. 4. Western blotting of renal cortex for tissue ferritin after the
1 week, every other day, iron treatment protocols. Only minimal fer-
ritin expression was seen in control kidney samples (C). Iron sucrose
(FeS) treatment clearly increased tissue ferritin expression. A lesser,
but still significant, increase in ferritin was apparent following iron glu-
conate (FeG) treatment. In contrast, neither iron dextran (FeD) nor
iron oligosaccharide (FeOS) caused any ferritin increments (not de-
picted; see Fig. 5).
to either FeG or FeS treatment. However, in striking
contrast to plasma (where FeD caused the greatest MDA
increases), in renal cortex, MDA increments resulted
from only FeG and FeS, but not FeD injection (Fig. 3B).
The heart was relatively resistant to iron-mediated lipid
peroxidation, as only FeS caused any increase in cardiac
MDA values (above the 95% confidence limits) (Fig. 3C).
Thus, in composite, these MDA results indicate that while
all of the test iron compounds can evince lipid peroxida-
tion, the degree to which this occurs depends on the par-
ticular tissue target (e.g., plasma, kidney, or heart) and
the particular drug (FeS, FeG, or FeD) involved.
Renal cortical ferritin and HO-1 protein expression.
Slight ferritin expression was seen in control renal cor-
tical tissue samples (Fig. 4). FeG and FeS each increased
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Fig. 5. Western blot densitometric analysis of renal cortical ferritin ex-
pression. Neither iron dextran (FeD) nor iron oligosaccharide (FeOS)
induced any change in renal cortical ferritin levels, as assessed by West-
ern blotting. In contrast, iron gluconate (FeG) and iron sucrose (FeS)
each raised renal cortical ferritin levels, compared to the control tis-
sue samples (P < 0.01 and P < 0.0001, respectively). The increase was
significantly greater with FeS vs. FeG (P < 0.03).
ferritin levels, rising ∼2× and ∼4× over control values,
respectively (Fig. 5). The increase was statistically greater
with FeS, in comparison to FeG treatment (P < 0.03).
Neither FeD nor FeOS caused any discernible ferritin
increase (i.e., above control values).
In contrast to ferritin, none of the treatments caused
any clearly discernible change in HO-1 protein expres-
sion (data not shown). In contrast, renal cortex obtained
18 hours postinduction of rhabdomyolysis-induced acute
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Fig. 6. Heme oxygenase- 1(HO-1) mRNA levels in renal cortex 4 hours
following intravenous iron dextrose (FeD), iron sucrose (FeS), iron glu-
conate (FeG), or iron oligosaccharide (FeOS) injection. Excepting FeD,
all of the iron preparations induced an approximate doubling of HO-1
mRNA levels, consistent with the induction of oxidative stress in renal
cortex.
renal failure showed prominent HO-1 induction (seen at
32 kD), confirming the adequacy of the employed West-
ern blot analysis.
Renal cortical HO-1 mRNA expression. As shown
in Figure 6, by 4 hours postinjection, FeS, FeG, and
FeOS each caused an approximate doubling of HO-
1 mRNA levels (P < 0.0001 for each vs. controls). In
striking contrast, FeD caused no change in renal corti-
cal HO-1 mRNA, with values being virtually identical
to control values. Of note, these results paralleled the
above-described MDA values, whereas both FeG and
FeS caused an approximate 30% increase in renal cor-
tical MDA, FeD did not raise renal MDA levels.
Renal histology. There was no definitive evidence of
renal histologic injury (Figs. 7 to 9), as discerned by light
microscopy (which was the reason for undertaking the
electron microscopy analyses). FeS, and to a lesser ex-
tent FeG (but not FeD or FeOS) did induce histologic
damage, as assessed by electron microscopy. The most
notable change was glomerular iron accumulation, tak-
ing the form of electron dense aggregates which were
most prominent in the mesangium and in endothelial
cells. Additionally, occasional large iron deposits could
be found in podocyte cell bodies (Fig. 8B). The foot pro-
cesses remained well preserved. Glomerular endothelial
deposits were associated with moderate to marked en-
dothelial cell swelling, observed in ∼40% of glomeru-
lar capillary loops (for example, see Fig. 7B). This led to
focal or diffuse obliteration of endothelial fenestrations
along the glomerular basement membrane. Noteworthy
was the complete absence of any discernible iron accumu-
lation (and attendant endothelial injury) with either FeD
or FeOS treatment (e.g., Fig. 9B). In none of the samples
analyzed by electron microscopy could proximal tubu-
lar iron accumulation, or histologic evidence of tubular
injury, be observed. However, with FeS treatment, occa-
sional empty vacuoles were observed in proximal tubular
cells (suggesting prior iron trafficking through proximal
tubular cells).
HK-2 cell experiments
% LDH release. After 3-day exposures to 100 lg/mL
of FeS, a marked increase in % LDH release was ap-
parent (Fig. 10B). FeG caused only a slight, but signif-
icant, increase in LDH release (P < 0.05). Conversely,
neither FeD nor FeOS increased LDH release above con-
trol values.
Cytochrome c release. As a second marker of cellu-
lar/mitochondrial injury, cytochrome c levels remaining
in adherent HK-2 cells in the above experiment were as-
sessed. As shown (Fig. 10A), there was no discernible loss
of cellular cytochrome c following either FeG, FeD, or
FeOS treatment. However, cytochrome c was decreased
by ∼95% in the cell pellets obtained following FeS
treatment.
Gross appearance of HK-2 cells following incubation
with test iron preparations. The cells which were har-
vested for cytochrome c analysis appeared grossly dif-
ferent in visual appearance. There was a distinct, dark
brownish discoloration of cells treated with FeG and FeS,
with the latter inducing the most profound color change
(Fig. 11). In contrast, neither FeOS nor FeD caused any
cell color change. Thus, gross cell appearance suggested
the following gradations of cell iron accumulation: FeS >
FeG vs. none with FeOS or FeD (paralleling degrees of
toxicity).
Electron microscopic evaluation of HK-2 cells. The
normal appearance of control HK-2 cells is shown in
Fig. 12A. In particular, there were frequent plasma mem-
brane microvilli seen, and in some instances, tight junc-
tions were observed (data not shown). Cells incubated
with FeS manifested marked accumulation of electron-
dense deposits within the cytoplasm, indicative of iron
uptake (Fig. 12B). These deposits appeared to be in
membrane-associated vacuoles. FeG treatment also led
to iron uptake (Fig. 13A), albeit to a lesser degree than
observed with FeS. The iron deposits with FeS appeared
larger than those seen with FeG, and in some cases, the
former took on a “tangled rope like” appearance within
cytosolic vacuolar structures (e.g., Fig. 14A). In contrast,
neither FeD (Fig. 13B) nor FeOS (Fig. 14B) demonstrated
any cytoplasmic iron accumulation. Despite the evidence
that mitochondria were targets of injury (based on cy-
tochrome c release and in vivo mitochondrial degenera-
tion), the iron treatments did not seem to perturb HK-2
mitochondrial structure (suggesting rapid mitochondrial
disruption/elimination following 3 days of injury).
Assessment of whether parenteral iron loading induces
tubular cytoresistance. As shown in Figure 15, tubules
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Fig. 7. Electron micrograph of normal
mouse renal cortex (A) and renal cortex after
1 week of every other day iron sucrose (FeS)
treatment (B). Note the presence of normal
endothelial fenestrations in the control tissue
(A). FeS treatment caused variable degrees
of endothelial cell swelling (∗), resulting in
focal narrowing or closure of capillary loops
with loss of fenestrae. Foci of iron deposition
were also observed in endothelial cells (e.g.,
see arrow).
Fig. 8. Electron micrographs of mouse renal
cortex following 1 week of every other day
iron sucrose (FeS) treatment. Extensive black
deposits of iron are present in the mesangium,
and to a lesser extent in endothelial cells (A).
Focal iron deposition was also observed in
podocytes but with preservation of foot pro-
cesses (B).
Fig. 9. Electron micrograph of mouse renal
cortex following 1 week of every other day
iron gluconate (FeG) (A) or iron dextran
(FeD) (B) treatment. FeG treatment led to
extensive iron deposition in glomerular struc-
tures (A). Conversely, FeD injections resulted
in no discernible iron deposition. Not de-
picted, iron oligosaccharide (FeOS) injections
also were not associated with discernible iron
accumulation in kidney, as assessed by elec-
tron microscopy.
isolated from FeS and control mice had identical degrees
of viability under control incubation conditions (∼10%
LDH release). No significant differences in tubule injury
were apparent with either the antimycin A or with the hy-
poxic challenge. In contrast, the FeHQ challenge caused
significantly less tubule injury in FeS pretreated mice,
with an approximate 50% decrease in FeHQ-mediated
LDH release being observed (i.e., % LDH released above
control values 15% vs. 7% for control vs. FeS pretreated
tubules, respectively). Thus, these results indicated that
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Fig. 10. Cytochrome c (cyt c) (A) and lactate
dehydrogenase (LDH) (B) loss from human
kidney (HK-2) cells in response to 3-day 100
lg/mL iron exposures. Cytochrome c levels re-
mained at, or near, control values with iron
dextran (FeD), iron oligosaccharide (FeOS),
or iron gluconate (FeG) treatment. Con-
versely, iron sucrose (FeS) treatment caused
massive loss of cellular cytochrome c. As
shown in (B), FeS, and to a lesser extent FeG,
caused significant LDH release, compared to
control values.
FeG FeSControl FeD FeOS
Fig. 11. Pelleted human kidney (HK-2) cells after 3 days of control incubations, or exposure to 100 lg/mL of either iron dextran (FeD), iron
oligosaccharide (FeOS), iron gluconate (FeG), or iron sucrose (FeS) treatment. The gross appearances of the FeD- and FeOS-exposed cells were
identical to that of the control cells. However, FeS, and to a lesser extent FeG, caused prominent iron staining. Subsequent electron microscopy
analysis confirmed intracellular FeS and FeG iron accumulation.
Fig. 12. Electron micrographs of human kid-
ney (HK-2) cells after control incubation (A)
or following 3-day iron sucrose (FeS) treat-
ment (B). As shown (B, see arrow for exam-
ple), there was extensive iron uptake by the
HK-2 cells. In the bottom right hand corner
of (B), iron appears to be in the internaliza-
tion process.
FeS iron was capable of impacting in vivo proximal tubu-
lar cells.
DISCUSSION
Although several reports have raised concerns of
potential adverse consequences of parenteral iron ad-
ministration to renal disease patients [6–12], it remains
unclear as to whether differing degrees of cytotoxicity ex-
ist amongst currently employed iron preparations. Such
a possibility is suggested by the fact that variable carbo-
hydrate structures are used to “shield” each compound’s
iron content; thus, formulation differences might impact
iron’s cytotoxic effects. Iron-induced oxidative stress is
widely accepted as a critical mediator of diverse forms
of glomerular and tubulointerstitial renal disease [26–
29]. Thus, intravenous iron administration could poten-
tially contribute to renal disease progression. Oxidative
stress can also exacerbate systemic inflammation [18–22]
and atherogenesis [12–17]. That these latter two condi-
tions negatively impact patient survival on dialysis [13,
18, 23] underscores parenteral iron’s potential to exert
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Fig. 13. Electron micrographs of human kid-
ney (HK-2) cells after incubation for 3 days
with either iron gluconate (FeG) (A) or iron
dextran (FeD) (B). Cells treated with FeG
had obvious iron incorporation (see arrow for
an example). Conversely, no iron uptake was
seen following FeD treatment.
Fig. 14. Electron micrographs of human kid-
ney (HK-2) cells after 3 days of either iron
sucrose (FeS) (A) or iron oligosaccharide
(FeOS) treatments (B). In addition to the
punctate intracellular FeS iron depicted in Fig.
12B, in some cells the iron assumed a tan-
gled filamentous appearance (A). As shown
in the right hand panel, FeOS exposure [as
with iron dextran (FeD), Fig. 13B] caused no
discernible intracellular iron uptake.
adverse effects. In light of these considerations, this
study addressed whether relative differences in toxicity
exist among four representative parenteral iron formula-
tions, and if so, what are some potential underlying de-
terminants thereof.
In a previous study from this laboratory [5], we posited
that marked differences in cytotoxicity do, in fact, ex-
ist among four intravenous iron formulations, with the
following relative rank order of toxicity: FeS  FeG 
FeD = FeOS. However, this conclusion was based solely
on in vitro experiments which predominantly relied on
cellular LDH release as a biologic readout. Furthermore,
those experiments were, in large part, conducted using
suprapharmacologic iron concentrations. Thus, at least
two important questions remained to be addressed: (1)
might differential iron toxicity also be expressed at clini-
cally relevant iron concentrations? and (2) might toxico-
logic differences, as defined in vitro, also be expressed in
an in vivo setting?
We previously noted that FeS toxicity had as a correlate
acute mitochondrial dysfunction [5]. This conclusion was
based on findings that cell exposure to 1 mg/mL of FeS
iron caused rapid and profound (∼90%) ATP depletion
in freshly isolated mouse proximal tubules. NaK-ATPase
inhibition (ouabain) did not abrogate FeS-induced ATP
declines, indicating that decreased mitochondrial ATP
production, rather than increased ATP consumption,
was likely responsible. The present study expands on
these initial observations in two important ways: (1) rela-
tive degrees of mitochondrial dysfunction/ATP declines
have been delineated for each of the above iron formu-
lations; and (2) a full dose-response relationship for each
test agent has been defined. Of note, the three lowest
test iron dosages (30, 60, and 125 lg iron/mL) fall within
a clinically achievable plasma iron concentration range
(e.g., ∼150 lg/mL following ∼500 mg intravenous iron
infusion). As shown in Figure 1, the extent of ATP reduc-
tions which followed iron exposures indicated an iden-
tical rank order of compound toxicity to that which we
previously reported (i.e., FeS  FeG  FeD = FeOS)
[5]. Furthermore, FeS and FeG caused statistically sig-
nificant ATP declines even with a 30 to 60 lg/mL iron
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Fig. 15. Injury to proximal tubular segments harvested from either
control mice or mice treated 18 hours previously with intravenous iron
sucrose (FeS). There was no difference in cell viability between control
tubules and prior FeS-exposed tubules under normal incubation condi-
tions. FeS pretreatment induced significant protection against in vitro
iron [iron-hydroxyquinoline (HQ)]-induced oxidant injury (P < 0.01).
However, this protection appeared to be specific for oxidant injury, as
no difference in lactate dehydrogenase (LDH) release was apparent be-
tween the groups which were subjected to the antimycin A or hypoxic
challenges.
concentration range. Conversely, FeD and FeOS required
1 mg/mL of iron to induce even minimal ATP declines.
Thus, these findings indicate that up to 30-fold differ-
ences in relative toxicity exist amongst selected intra-
venous iron preparations (e.g., FeS vs. FeD).
In a “Letter to the Editor” [46], Van Wyck strongly
opined, but in the absence of supporting data, that the
alkaline pH (∼10.5) of the stock FeS solution was the
explanation for our previous findings [5] of preferential
FeS cytotoxicity. Indeed, we, as well as others, have pre-
viously reported that alkaline conditions can decrease
cell viability, particularly when those cells are challenged
with superimposed attack (e.g., hypoxia) [46]. However,
the current results conclusively rule out Van Wyck’s “pH
hypothesis.” First, even at the highest dosage employed
(1 mg/mL), FeS addition to isolated tubule suspensions
induced a relatively small change in tubule suspension
pH (rising from 7.44 to 7.80). Second, with subsequent
serial dilutions of the FeS stock solution (from 500 →
30 lg/mL), no discernible changes in isolated tubule sus-
pension pH were detected, and yet dramatic ATP re-
ductions still occurred (dissociating these two events).
Finally, alkaline sucrose addition to isolated tubules (to
recreate FeS maximal pH effect) tended to raise, rather
than lower, tubule ATP content and it failed to reproduce
FeS cytotoxic effect (i.e., LDH release). Clearly then, as
discussed below, alternative mechanisms for preferential
FeS cytotoxicity must exist.
To gain further support for the concept that parenteral
iron toxicity is expressed at, or potentially mediated by,
mitochondrial injury, a second end point of mitochondrial
damage, notably cytochrome c release, was assessed in
cultured proximal tubule (HK-2) cells following a 3-day
100 lg/mL iron challenge. Recent work from this labo-
ratory [31] has demonstrated that following iron-induced
mitochondrial toxicity, cytochrome c rapidly leaves the
mitochondrion, traverses the cytosol, crosses an intact
plasma membrane, and eventuates in the extracellular
space [31]. Thus, total cellular (and not just mitochon-
drial) cytochrome c loss serves as an index of mitochon-
drial damage. As shown in Figure 10, FeS treatment
induced almost complete cytochrome c loss from HK-
2 cells. In contrast, FeG caused a nonsignificant trend
toward cell cytochrome c reductions, whereas FeD and
FeOS had no discernible effect. These results were par-
alleled by the accompanying LDH release data: 45%,
18%, and 5% for FeS, FeG, and FeD/FeOS, respectively.
Clearly then, these HK-2 cell results fully support the
relative toxicity profiles gleaned from the above iso-
lated mouse proximal tubule experiments (FeS > FeG >
FeD or FeOS), and further indicate that the mitochon-
drion is a critical intracellular iron target. That HK-2
cytotoxicity could again be expressed at a clinically
achievable iron concentration underscores the potential
clinical relevance of these observations.
The cells which were collected from the above de-
scribed HK-2 cell experiments provided a striking, and
unexpected, clue as to why the four test iron agents ex-
ert differential cytotoxicity. As depicted in Figure 11,
varying amounts of brownish cell staining was apparent,
with its degree exactly paralleling the rank order toxicity
data: FeS  FeG  FeD = FeOS = controls. To deter-
mine whether these color changes simply reflected iron
adherence to, or staining of, the plasma membrane vs.
cellular iron incorporation, electron microscopic analy-
ses were performed. As illustrated in Fig. 12B, FeS iron
was clearly internalized within HK-2 cells. FeG induced
similar, albeit less pronounced, intracellular iron loading
(Fig. 13A). In contrast, there was a complete lack of iron
internalization following 3 days of either FeD or FeOS
treatment. Thus, these findings strongly suggest that the
differential cytotoxicity of these test agents reflects their
differing capacities to gain intracellular access. The rea-
son for this differential uptake remains unknown. In pilot
data not presented, FeS uptake appeared to be indepen-
dent of a possible sucrose transport pathway, given that
excess sucrose addition to FeS-challenged HK-2 cells nei-
ther diminished FeS uptake or the resultant LDH release.
The final goal of this study was to determine whether
in vivo correlates of parenteral iron toxicity might exist.
To achieve this goal, a relatively large amount of iron
(2 mg) was employed. While this obviously exceeds a
clinically relevant dosage, it should be noted that acute,
rather than chronic, toxicity was sought. Furthermore, a
large dose was employed to facilitate potential iron de-
tection/localization in renal histologic sections. Based on
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these experiments, it is clear that in vivo iron toxicity can,
indeed, be expressed, as delineated by the following ob-
servations. First, lipid peroxidation results, as indicated by
marked plasma MDA increments. Second, these plasma
MDA increases can have tissue correlates, as denoted by
renal cortical, and to a much lesser extent myocardial,
lipid peroxidation. Third, patterns and degrees of lipid
peroxidation differ, according to the iron compound em-
ployed and the specific target organ involved (see Re-
sults section). Fourth, renal cortical oxidative stress was
confirmed by documenting HO-1 mRNA increases with
different test iron compounds. Surprisingly, no corre-
sponding HO-1 protein increments resulted, suggesting
that despite the mRNA increases, a failure of normal HO-
1 message translation may result. Finally, renal cortical
iron exposure was confirmed by documenting increased
tissue ferritin content following FeS and FeG (but not
FeD or FeOS) treatment. It is noteworthy that, as with the
in vitro results, differential in vivo iron-mediated “toxic-
ity” was apparent. For example, the rank order of renal
cortical ferritin induction paralleled the in vitro toxic-
ity profiles (FeS > FeG > FeD or FeOS). Furthermore,
FeS and FeG each raised renal cortical MDA and HO-1
mRNA, whereas FeD failed to induce either of these two
results. Clearly, then, differential, and seemingly parallel,
toxicities can be expressed in both in vivo and in vitro
settings.
If differential parenteral iron toxicity is, indeed, depen-
dent on differing degrees of iron uptake (as suggested by
the HK-2 cell experiments), it would be predicted that
greater renal cortical iron accumulation would follow
FeS and FeG, vs. FeD or FeOS treatments. Indeed, the
electron microscopy evaluations of renal cortex obtained
following parenteral iron therapy were entirely consis-
tent with this hypothesis. FeS, and to a somewhat lesser
extent FeG, treatment led to prominent iron accumula-
tion within the mesangium, glomerular endothelial cells,
and to a lesser extent, in podocytes. Conversely, FeD or
FeOS injections caused no discernible renal iron deposits.
That glomerular endothelial swelling/fenestrae loss was
a correlate of FeS, and to a lesser extent of FeG, accumu-
lation indicates the pathogenic potential of this process.
Somewhat surprising was the lack of proximal tubular
iron deposition, at least as could be discerned by elec-
tron microscopy. However, there can be little doubt that
intravenous iron injections can impact proximal tubular
cell homeostasis, given that tubules isolated from FeS-
treated mice manifested partial cytoresistance to sub-
sequent FeHQ-induced oxidant attack. Noteworthy in
this regard are recent findings of Nath et al [26]. These
workers demonstrated that recurrent iron-induced oxi-
dant injury, although eliciting transient cytoresistance, ul-
timately culminates in chronic tubulointerstitial nephritis
[26]. These observations, coupled with the findings that
FeS induced glomerular iron deposits, endothelial injury,
and tubular cytoresistance, raise the concern that chronic
parenteral iron treatment could potentially evoke renal
damage.
CONCLUSION
The present study provides additional support for the
concept that parenteral iron formulations have intrinsic
cytotoxic potentials, and that the degrees to which these
toxicities are expressed is critically dependent on the na-
ture of carbohydrate polymers employed. The latter ap-
pear to determine cellular iron uptake, both in vivo and
in vitro, and hence the capacity of these compounds to in-
duce their cytotoxic effects. That these compound(s) can
up-regulate renal cortical HO-1 mRNA and tissue fer-
ritin, and induce tissue lipid peroxidation, indicate that
oxidative injury (e.g., directed at mitochondria) is the
likely pathogenic pathway by which parenteral iron toxi-
city results. While the clinical relevance of these findings
remains speculative at this time, caution would appear
to be warranted when administering these compounds
to patients with renal disease. Indeed, given that intra-
venous iron can damage normal kidneys, its potential
nephrotoxicity might be even greater in the presence of
active nephropathy. Of considerable interest in this re-
gard, Agarwal et al [48] recently reported that FeS ad-
ministration to chronic renal disease patients increases
both proteinuria and proximal tubular enzymuria. This
serves to underscore the above concerns.
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